ALK and non-small cell lung carcinoma: As a consequence, small molecular ALK inhibitors such as Crizotinib6 and Ceritinib7 (Figure 1) were approved for the treatment of ALK-driven NSCLC via blocking ALK and its downstream signal transduction pathways.